Eiger BioPharmaceuticals, Inc.
EIGRDelisted Apr 25, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001305253
Eiger BioPharmaceuticals, Inc. was delisted on Apr 25, 2024; its insiders filed their last Form 4 on Nov 2, 2023; 43 institutions reported holding it in 13F filings for Q4 2023, worth $4.16M in total; no superinvestor held it.
Key figures
- Market cap
- –
- Not available
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 43
- Q4 2023, −8 vs. previous quarter
- 13F value
- $4.16M
- Reported value at the end of Q4 2023
- Superinvestors holding
- 0
- At the end of Q4 2023
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2023
- $15.8M
- +17.0% year over year
- Net income, FY2023
- -$75.0M
- No comparable prior period
- Free cash flow, FY2023
- -$74.8M
- No comparable prior period
- Revenue, Q4 FY2023
- $3.80M
- +41.1% year over year
Revenue flow, FY2023
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2023: $75.0M (475.3% of revenue).
Superinvestors holding EIGR, Q4 2023
Go to the superinvestors tabNo superinvestor reported holding EIGR at the end of Q4 2023.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Eiger BioPharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 2, 2023 (view filing)9:21 PM ET | Oct 31-Nov 2 | 2 days | Kayne Richard A10% Owner | PPurchase | +278.2K | $0.2617 | +$72.8K | +5.5%5.38M after | 5 lots |
| Nov 2, 2023 (view filing)9:14 PM ET | Oct 31 | 2 days | Kawas Leen10% Owner | PPurchase | +24.3K | $0.262 | +$6.37K | +0.6%4.39M after | 2 lots |
| Mar 21, 2023 (view filing) | Mar 17 | 4 days | Mayer Eldon C. IIIEx VP & Chief Commerc. Officer | SSale | −4.39K | $1.07 | −$4.70K | −7.3%56.1K after | 2 lots |
| Jan 25, 2023 (view filing) | Jan 23 | 2 days | Dietz Thomas JohnDirector | PPurchase | +50.0K | $1.43 | +$71.5K | New position50.0K after | |
| Jan 3, 2023 (view filing) | Dec 29, 2022 | 5 days | Murray ChristineDirector | SSale | −5.00K | $1.22 | −$6.10K | −31.3%11.0K after | |
| Dec 27, 2022 (view filing) | Dec 22 | 5 days | Dietz Thomas JohnDirector | SSale | −22.5K | $1.17 | −$26.3K | −51.7%21.0K after | |
| Dec 27, 2022 (view filing) | Dec 22 | 5 days | Glenn Jeffrey SDirector | PPurchase | +100.0K | $1.28 | +$128.0K | +121.4%182.4K after | |
| Aug 18, 2022 (view filing) | Aug 16 | 2 days | Apelian DavidDirector | SSale | −5.00K | $9.81 | −$49.0K | −31.3%11.0K after | |
| Mar 14, 2022 (view filing) | Mar 14 | Same day | Ryali SriramChief Financial Officer | SSale | −2.27K | $5.60 | −$12.7K | −5.2%41.6K after | |
| Mar 14, 2022 (view filing) | Mar 14 | Same day | Mayer Eldon C. IIIEx VP & Chief Commerc. Officer | SSale | −1.66K | $5.60 | −$9.28K | −2.7%60.5K after |
Top 10 13F holders, Q4 2023
See all 43 holdersThe largest institutional positions in Eiger BioPharmaceuticals, Inc. at the end of Q4 2023; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ameriprise Financial Inc | 7,505,539 | $1.68M | 0.00% | −1,086,932−12.6% | Reduced |
| Propel Bio Management, LLC | 4,391,432 | $985.9K | 0.82% | +4,391,432 | New |
| 683 Capital Management, LLC | 2,100,000 | $471.4K | 0.05% | −550,000−20.8% | Reduced |
| Vanguard Group Inc | 1,820,767 | $408.8K | 0.00% | −143,535−7.3% | Reduced |
| BlackRock Inc. | 583,730 | $131.0K | 0.00% | −302,404−34.1% | Reduced |
| Geode Capital Management, LLC | 379,707 | $85.3K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 344,210 | $77.0K | 0.00% | +344,210 | New |
| RBF Capital, LLC | 338,733 | $76.0K | 0.00% | −52,532−13.4% | Reduced |
| Acadian Asset Management LLC | 174,088 | $38.0K | 0.00% | −63,946−26.9% | Reduced |
| State Street Corp | 146,781 | $33.0K | 0.00% | 00.0% | Unchanged |